Leukeran is a brand name for the medication chlorambucil, which is an alkylating agent used in the treatment of certain types of cancer. Here is some information about Leukeran:


Treatment of Cancer

Leukeran (chlorambucil) is primarily prescribed for the treatment of certain types of cancer, including chronic lymphocytic leukemia (CLL), lymphomas, and some types of ovarian cancer. It belongs to a class of drugs known as alkylating agents, which work by interfering with the DNA replication process in cancer cells, thereby inhibiting their growth and preventing them from multiplying.

Dosage and Administration

Leukeran is available in tablet form and is typically taken orally. The dosage and treatment duration will vary depending on the specific type and stage of the cancer being treated, as well as individual factors such as age, overall health, and response to the medication. It is important to follow the dosage instructions provided by a healthcare professional and not exceed the recommended dose.

Precautions and Potential Side Effects

Leukeran is a potent medication with the potential for side effects. Common side effects may include nausea, vomiting, loss of appetite, diarrhea, and fatigue. It can also suppress the bone marrow, leading to a decreased production of blood cells, which may increase the risk of infection, anemia, and bleeding.

Leukeran may also have long-term effects, including an increased risk of developing other types of cancer, such as secondary leukemia. It is important to discuss the potential risks and benefits of Leukeran with a healthcare professional.

Monitoring and Follow-Up

Regular monitoring, including blood tests and other medical evaluations, may be necessary during treatment with Leukeran to assess the response to therapy, monitor blood cell counts, and manage any potential side effects. It is important to attend all scheduled appointments and communicate any concerning symptoms to your healthcare team.

Consultation with Healthcare Professional

Leukeran is a prescription medication, and its use should be supervised by a healthcare professional experienced in the treatment of cancer. It is important to consult with an oncologist or hematologist to discuss your specific cancer diagnosis, determine the appropriate treatment plan, and assess the potential benefits and risks of Leukeran.

WARNING: Please consult with a healthcare professional or doctor for personalized advice and guidance regarding the use of Leukeran or any other medication for the treatment of cancer. They will be able to provide specific instructions based on your medical history and individual needs.


  1. ^ “Chlorambucil”National Cancer Institute. 17 September 2014. Archived from the original on 21 December 2016. Retrieved 19 December 2016.
  2. Jump up to:a b c d e f g h i “Chlorambucil”. The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
  3. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  4. ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
  5. ^ Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA (2000). “Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia”. N Engl J Med343 (24): 1750–7. doi:10.1056/NEJM200012143432402PMID 11114313.
  6. Jump up to:a b “Leukeran (Chlorambucil) Drug Information: Description, User Reviews, Drug Side Effects, Interactions – Prescribing Information at RxList”RxListArchived from the original on 2015-12-22. Retrieved 2015-12-21.
  7. ^ “chlorambucil – CancerConnect News”CancerConnect NewsArchived from the original on 2015-12-22. Retrieved 2015-12-21.
  8. ^ “Leukeran” (PDF). Archived (PDF) from the original on 2015-12-22.
  9. ^ “Chlorambucil”Archived from the original on 2017-01-03.
  10. ^ Di Antonio, Marco; McLuckie, Keith I. E.; Balasubramanian, Shankar (2014). “Chlorambucil”Journal of the American Chemical Society136 (16): 5860–5863. doi:10.1021/ja5014344PMC 4132976PMID 24697838.
  11. ^ “chlorambucil | C14H19Cl2NO2 – PubChem”pubchem.ncbi.nlm.nih.govArchived from the original on 2015-12-22. Retrieved 2015-12-21.
  12. ^ Parker, Lorien J.; Ciccone, Sarah; Italiano, Louis C.; Primavera, Alessandra; Oakley, Aaron J.; Morton, Craig J.; Hancock, Nancy C.; Bello, Mario Lo; Parker, Michael W. (2008-06-27). “The anti-cancer drug chlorambucil as a substrate for the human polymorphic enzyme glutathione transferase P1-1: kinetic properties and crystallographic characterisation of allelic variants” (PDF). Journal of Molecular Biology380 (1): 131–144. doi:10.1016/j.jmb.2008.04.066hdl:2108/101037ISSN 1089-8638PMID 18511072.
  13. ^ “chlorambucil | C14H19Cl2NO2 – PubChem”pubchem.ncbi.nlm.nih.govArchived from the original on 2015-12-22. Retrieved 2015-12-21.
  14. ^ “Chemical Approaches to the Discovery and Development of Cancer: Serendipity and Chemistry”Archived from the original on 2014-06-23. Retrieved 2016-11-24.
  15. ^ Gilman, A.G.; Rall, T.W.; Nies, A.S.; Taylor, P. (1990). Goodman and Gilman’s The Pharmacological Basis of Therapeutics. New York: Pergamon.
  16. ^ Anslow, W. P. (1948). “The intravenous, subcutaneous and cutaneous toxicity of bis(-chloroethyl) sulfide (mustard gas) and of various derivatives”. J. Pharmacol. Exp. Ther.